SEC Form 4 · accession 0001209191-19-013586
Forte Biosciences, Inc. · FBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lori Anne Kunkel
Officer — Acting-Chief Medical Officer
Period of report
Jan 11, 2019
Accepted (ET)
Feb 26, 2019 · 4:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419041
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $9.27 | Jan 11, 2019 | A | 35,000 | A | — | Jan 10, 2029 | Common Stock | 35,000 | 35,000 | D |
Explanation of responses
- F1The stock option vests in full on May 26, 2019.